GlassScriptPhysician profile
Earl Y Young
NPI 1881645661
$1,821.54
in general payments reported to CMS, 2019-2025
19 companies · $209 in 2025
The $209 reported for 2025 was more than what 75% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $167 · 2021: $313 · 2022: $268 · 2023: $359 · 2024: $386 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $954.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $260.87 | 2019-2025 | Doc Band |
| Corium, LLC | $253.77 | 2021-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $183.07 | 2021-2024 | Qelbree |
| Pfizer INC. | $146.30 | 2020-2025 | |
| Advanced Respiratory, INC | $145.11 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $140.02 | 2020-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $124.61 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Glaxosmithkline, LLC. | $116.08 | 2020-2025 | Bexsero |
| Sanofi Pasteur INC. | $86.68 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $67.83 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.23 | 2020-2021 | |
| Neos Therapeutics, LP | $51.77 | 2019-2024 | Adzenys Xr-Odt |
| Kaleo, INC. | $42.01 | 2021-2024 | Auvi-Q |
| Adlon Therapeutics L.P. | $41.05 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $26.37 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $23.61 | 2025 | Neffy |
| Collegium Pharmaceutical, INC. | $21.66 | 2025 | Jornay Pm |
| Tempus Ai, INC | $19.70 | 2024 | |
| Phadia US INC. | $18.80 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Earl Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.